Mochi Health review

Mochi Health is a membership-based telehealth program, not a medication subscription with one all-inclusive price. Members complete an intake and meet virtually with a licensed clinician, who reviews their history and decides whether any prescription is appropriate. The membership advertises unlimited physician and care-team access, in-app coaching and messaging, 24/7 support, and nutrition help from registered dietitians. Medication can then be prescribed separately, with support for insurance paperwork when a branded drug is pursued. That structure offers more follow-up than a bare-bones prescription service, but paying the membership does not guarantee a prescription, a particular drug, insurance approval, or delivery of medication.

The program makes the most sense for someone who values recurring video access, nutrition support, and the ability to consider both cash-pay compounded medication and an insurance-dependent branded option. It is less compelling for a buyer who already has a trusted prescriber, needs frequent in-person examination, or wants the entire treatment cost fixed before entering payment information. Mochi also advertises access across all 50 states, but the first-month promotion and treatment availability can vary by state. Anyone primarily attracted by the low opening price should judge the service on its recurring cost and care model instead.

As of July 2026, the standard month-to-month membership is $79, with a new-member first month advertised at $39; Mochi states that the promotion is unavailable in some states. Medication and diagnostic services are excluded. As of July 2026, compounded semaglutide is advertised at $99 per month and compounded tirzepatide at $199 per month, with shipping included and the same advertised medication price across listed doses. That produces an as-of-July-2026 first-month total of $138 for the semaglutide path or $238 for the tirzepatide path, followed by $178 or $278 per month respectively. Branded medication is billed separately, and its cost depends on the selected product, insurance coverage, copay, prior authorization, and dispensing channel. Labs, genetic testing, and sleep-apnea assessments are described as options, but Mochi does not publish a universal lab price; any required testing could therefore raise the total.

The medication menu is genuinely broader than compounded-only services. Mochi’s current weight-loss page lists compounded semaglutide and tirzepatide alongside branded products including Wegovy, Zepbound, Ozempic, and Mounjaro, all subject to clinician review. Wegovy contains semaglutide and Zepbound contains tirzepatide; unlike compounded versions, these branded products have FDA-approved labeling. FDA says compounded drugs are not reviewed before marketing for safety, effectiveness, or quality and has reported dosing errors with compounded injectable GLP-1 products. It has also warned that semaglutide sodium and semaglutide acetate are different active ingredients from the base form used in approved products. Mochi says compounded prescriptions go to licensed partner pharmacies. A company quality-report page identifies Aequita Pharmacy as having supplied recent batches, but the broader site refers to multiple independent partners and does not establish that Aequita will fill every order. Before paying, a buyer still cannot reliably know which clinician-selected option will be available, what a branded prescription will cost after insurance, whether labs will be requested, or which pharmacy, formulation, concentration, additives, and injection supplies will accompany a compounded order. That verification burden is meaningful, not administrative trivia.

Use this sequence before entering payment details. It keeps program marketing, eligibility review and final billing terms separate.

Mochi's homepage describes monthly membership, provider access, coaching and support. It also displays compounded tirzepatide pricing and states that medications and diagnostic services are not included in the membership subscription. That separation is useful because it gives users a clearer way to calculate total cost.

Mochi is attractive to many cash-pay shoppers because of compounded GLP-1 pricing. The caveat is regulatory: compounded semaglutide or tirzepatide products are not FDA-approved products, even when legally prescribed. Users should ask about the pharmacy, formulation, dosing instructions and what happens as FDA shortage policy changes.

Mochi may fit people who value ongoing messaging, coaching and direct membership pricing more than a brand-only medication pathway. It is less straightforward for users who want only FDA-approved branded medication, because final medication choice depends on eligibility, state availability and provider discretion.

Mochi is often discussed as a more transparent membership model because the site presents provider access, dietitian support and medication options in one program. The review still needs to separate membership from medication and diagnostics. Mochi states that medications and diagnostic services are not included in the membership subscription. That line is important because many readers see a monthly membership and assume it includes the full treatment cost. For cash-pay shoppers, the medication quote, dose tier, shipping, pharmacy and renewal cadence are the main comparison points. For insured shoppers, the question is whether branded medication is available and whether the care team helps with coverage.

Mochi can be attractive because it discusses lower-cost compounded GLP-1 options, but that is also where readers need the most caution. FDA guidance says compounded GLP-1 products are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing. FDA has also warned about dosing errors, products arriving with inadequate refrigeration, fraudulent labels and semaglutide salt forms. A provider can still legally prescribe a compounded medication in specific circumstances, but a consumer should not treat it as the same thing as an FDA-approved brand-name product.

Mochi's best differentiator is not just medication access; it is the stated combination of medical providers and nutrition support. That can matter because GLP-1 users often need practical help with protein intake, constipation, nausea, hydration, meal size and muscle maintenance. A good Mochi plan should include clear escalation steps if side effects interfere with eating, if weight loss stalls, or if blood pressure or blood sugar medications need review. This is also where users should ask whether the dietitian support is included, how appointments are scheduled and whether care is synchronous, asynchronous or both.

Mochi should be compared against two different groups: compounded-first cash-pay providers and brand-name programs with insurance support. Against compounded providers, the deciding factors are pharmacy transparency, dose-tier pricing, shipping quality and how quickly clinicians respond. Against brand-name programs, the deciding factors are whether the lower visible price is worth accepting compounded-product uncertainty and fewer manufacturer-label protections. The user should also compare support depth. If dietitian access is meaningful and used regularly, Mochi may offer more practical help than a cheaper medication-only path. If the user only wants a vial shipped at the lowest price, the membership value may be weaker.

Mochi is strongest for users who want membership-based care and are open to compounded or brand options after a clinician review. It is weaker for users who want a brand-only pathway with no regulatory ambiguity. The trade-off to weigh: pricing can be attractive, but the compounded-product verification burden is higher. Compare Mochi against Fridays if promo cash-pay pricing is the main draw, against Hims if you want branded options without insurance, and against Noom Med if behavior support is more important than pharmacy flexibility.